FINALY , this is whare the big bucks should start coming in for RHT .
The Collaboration Agreement progresses the Company’s strategy of expanding into new geographies for both clinical trial and diagnostic services. Liver cirrhosis aetiologies in Japan are increasing in step with an increase in alcoholic-related disease (ALD) and non-alcoholic steatohepatitis (NASH).
Furthermore, Japan is among the largest pharmaceutical markets in the world with sales revenues totalling over USD $100 billion in 2021 for the sale of both prescription and non-prescription pharmaceuticals. Working with an established entity with over 20 years of experience in CRO services in the Japanese market will assist in Resonance’s fast-tracking of growth in Japan for both its clinical trial and diagnostic services.
RHT Price at posting:
6.5¢ Sentiment: None Disclosure: Held
